Graft-versus-host disease (GVHD) causes significant morbidity and mortality in allogeneic hematopoietic stem cell transplantation (aHSCT), preventing its broader application to non-life-threatening diseases. We show that a single administration of a nondepleting monoclonal antibody specific for the coinhibitory immunoglobulin receptor, B and T lymphocyte associated (BTLA), permanently prevented GVHD when administered at the time of aHSCT. Once GVHD was established, anti-BTLA treatment was unable to reverse disease, suggesting that its mechanism occurs early after aHSCT. Anti-BTLA treatment prevented GVHD independently of its ligand, the costimulatory tumor necrosis factor receptor herpesvirus entry mediator (HVEM), and required BTLA expression by donor-derived T cells. Furthermore, anti-BTLA treatment led to the relative inhibition of CD4 + forkhead box P3  (Foxp3  ) effector T cell (T eff cell) expansion compared with precommitted naturally occurring donor-derived CD4 + Foxp3 + regulatory T cell (T reg cell) and allowed for graftversus-tumor (GVT) effects as well as robust responses to pathogens. These results suggest that BTLA agonism rebalances T cell expansion in lymphopenic hosts after aHSCT, thereby preventing GVHD without global immunosuppression. Thus, targeting BTLA with a monoclonal antibody at the initiation of aHSCT therapy might reduce limitations imposed by histocompatibility and allow broader application to treatment of non-life-threatening diseases.
Br ief Definitive Repor t
Replacement of an abnormal lymphohemato poietic system by allogeneic hematopoietic stem cell transplantation (aHSCT) from a healthy donor is an effective treatment for many dis orders of the hematopoietic system (Sykes and Nikolic, 2005; Copelan, 2006) . Induction of a mixed hematopoietic donorhost chimerism can induce longlasting tolerance to foreign tis sues without the need for lifelong immuno suppressive therapy (Kawai et al., 2008) . aHSCT therapy has been improved by better donor identification (Petersdorf et al., 2004) , more tolerable conditioning regimens (McSweeney et al., 2001) , and enhanced supportive care. However, significant treatmentrelated morbidity and mortality from chemotherapy, radiotherapy, infections, and graftversushost disease (GVHD) remain significant clinical problems. Therefore, aHSCT is commonly indicated only for treat ment of conditions where other treatment op tions are far inferior or lacking.
Costimulatory molecules of the CD28 and TNF families regulate GVHD, with inhibitory and activating receptors either decreasing or in creasing its severity (Tamada et al., 2000; Blazar et al., 2003; Xu et al., 2007) . B and T lympho cyte associated (BTLA) is an inhibitory immu noglobulin superfamily receptor, whose ligand is the TNF receptor herpesvirus entry mediator expressed by recipient mice might regulate GVHD in this model, we used BTLA / CB6F1 hosts as recipients of BTLA / BM and splenocytes (Fig. S1 a) . BTLA / donor cells induced similar GVHD in BTLA +/ and BTLA / hosts, which is comparable to GVHD by WT donor cells (Fig. 1 a) . Col lectively, these data suggest that BTLA does not normally regu late GVHD.
Because BTLA generates inhibitory signals and functions in autoimmunity (Watanabe et al., 2003) , malaria infection (Lepenies et al., 2007) , and intestinal inflammation (Steinberg et al., 2008) , we wondered whether harnessing the inhibitory effects of BTLA on the immune response by forced engage ment would attenuate GVHD. To test this, we compared the effects of an agonistic nondepleting antiBTLA monoclonal antibody Lepenies et al., 2007) , 6A6, administered at the time of aHSCT (Fig. 1 b) with an iso type control antibody, PIP, that recognizes bacterial GST (Gronowski et al., 1999) . Mice treated with PIP showed sim ilar progression of GVHD (Fig. 1, a and b) , with clinical scores between 3 and 4 persisting for >140 d (Fig. S1 b) . GVHD was associated with thickening of the lamina propria and muscularis, with severe inflammation and ulceration of (HVEM) and which has only been examined in a nonirradi ated model of chronic allostimulation without classical GVHD where donor cells lacking BTLA failed to persist . The role of BTLA in aHSCT using irradiated recipients, in which clinical symptoms and pathology similar to human GVHD develop, has not been examined.
RESULTS AND DISCUSSION
To determine the role of BTLA in the development of GVHD, we first examined WT and BTLA / donor mice (Watanabe et al., 2003) using a nonlethal parentintoirradiated F1 model of aHSCT (Stelljes et al., 2008) . In this model, GVHD results from partial MHC mismatch between H2 b haplotype donor cells and lethally irradiated H2 b/d haplotype recipients. BM and splenocytes from WT or BTLA / mice on the C57BL/6 background were transferred into lethally irradiated CB6F1 recipients (Fig. 1 a) . Transplantation of WT donor cells into CB6F1 recipients caused body weight loss of 30% and clinical scores (Cooke et al., 1996) (e) Lethally irradiated BALB/c mice received TCD-BM alone (green lines and closed squares, n = 10) or in combination with splenocytes from C57BL/6 mice and control antibody PIP (red lines and open circles, n = 10) or 6A6 (blue lines and closed circles, n = 10) on the day of BMT. Shown are cumulative data from two independent experiments. Weight and clinical score data shown are mean ± SD. Data are representative of two independent experiments with five mice per group or cumulative data from independent experiments as indicated. P-values of >0.05 are considered not significant (n.s). ***, P < 0.001.
Br ief Definitive Repor t
within 30 d after aHSCT from severe GVHD (Fig. 1 e, right) . Although mice that received the antiBTLA treatment were not fully protected from GVHD, with clinical scores ranging from 1 to 3 (Fig. 1 e, middle) and slightly more weight loss than the control group that had received T cell-depleted BM cells (BMCs [TCDBMs] ) alone ( Fig. 1 e, left) , 70% of recipients treated with 6A6 survived for >200 d after aHSCT.
Although the precise molecular targets of BTLA signaling are still obscure (Gavrieli and Murphy, 2006; Wu et al., 2007) , BTLA engagement by HVEM can inhibit T cell pro liferation in vitro and promote tolerance induction in vivo (Liu et al., 2009) . Therefore, we asked if antiBTLA treatment alters donor T cell proliferation or IL2 production in vivo. CFSElabeled donor splenocytes were transferred into CB6F1 recipients that were treated with PIP, 6A6, or 6F7. Donor T cell proliferation was assessed after aHSCT and, by 3 d after aHSCT, reduced CFSE levels sug gested that proliferation had occurred (Fig. 2 e) . CD4 + T cells had reduced proliferation after treatment with 6A6 and 6F7 antibodies 3 d after aHSCT (Fig. 2 e, middle), and the total accumulation of donor CD4 + T cells was significantly reduced compared with control (P < 0.0018 and P < 0.0083; Fig. 2 b) . In contrast, CD8 + T cell proliferation and accu mulation were not significantly affected by 6A6 treatment (P < 0.8489; Fig. 2 , a and e, left). As 6F7 treatment leads to partial depletion of cells, we also assessed the level of annexin V binding, which is an indicator of early apoptosis. Mice treated with 6F7, but not PIP or 6A6, showed increased bind ing of annexin V on CD4 + and CD8 + T cells 7 d after aHSCT, which was not observed on day 3 (Fig. S1 g ).
Although accumulation of CD4 + T cells was lower in 6A6 treated than in PIPtreated mice, the production of IL2 7 d after aHSCT was not statistically different (Fig. S2, a and b) . A small but significant reduction in IFN and IL4, but not IL17, production was observed in 6A6treated mice com pared with controls ( Fig. S2, a and b) . In summary, 6A6 ad ministered at the time of aHSCT reduced the proliferation and accumulation of donorderived CD4 + Foxp3  effector T cells (T eff cells) without inducing anergy, inhibiting IL2 production or causing major alterations in cytokines.
These effects were suggestive of the actions of CD4 + Foxp3 + regulatory T cells (T reg cells) expressing the tran scription factor forkhead box P3 (Foxp3; Hori et al., 2003) . T reg cells have recently been reported to play a significant role in regulating GVHD (Taylor et al., 2002; Edinger et al., 2003b) , and there are ongoing clinical trials aimed directly at the use of T reg cells as an intervention in human GVHD (NCI clinical trial NCT00725062).
To determine whether 6A6 treatment influences T reg cells, we measured the accumulation and proliferation of donorderived T eff cells after aHSCT (Fig. 2, c and e, right) . In PIPtreated recipients that developed GVHD, significantly fewer T reg cell were detected 7 d (P < 0.0393) after aHSCT when compared with recipients that received either anti BTLA treatment 6A6 or 6F7 (Fig. 2 c) . Therefore, anti BTLA treatment inhibits the proliferation of T eff cells yet the colon (Stelljes et al., 2008; Fig. S1 c, bottom) . In contrast, a single treatment of 10 µg/g body weight of 6A6, given at the time of aHSCT, prevented GVHD completely, with weight loss and GVHD similar to the syngeneic control group (Fig. 1 b) for 140 d after aHSCT (Fig. S1 b) . Furthermore, 6A6treated mice had no histological evidence of GVHD in the colon (Fig. S1 c, top) . Thus, a single administration of antiBTLA antibody eliminates weight loss, histological changes, and clinical signs of GVHD.
We next asked if 6A6 acted by simply depleting donor cells that express BTLA. As a positive control, we included a de pleting murine antiBTLA antibody, 6F7 Truong et al., 2009) . CFSElabeled donor cells were trans ferred into WT recipients that also received PIP, 6A6, or 6F7 antibody. 2 d after transfer, we found similar numbers of CFSE + cells in mice that received either PIP or 6A6 antibody (Fig. S1 d, left) and no significant differences between numbers of CD19 + , CD4 + , or CD8 + lymphocytes (Fig. S1 d, right) . Treatment with 6F7 caused a significant depletion of CFSE + lymphocytes, particularly from the CD19 + cell population ( Fig. S1 d) . Furthermore, surfacebound 6A6 was detectable on live donorderived cells in vivo up to 7 d after transfer (Fig. S1 e) . In addition, 6A6 treatment was unable to prevent GVHD caused when BTLA / donors were used as a source of BM for aHSCT (Fig. S1 f) . Thus, 6A6 does not deplete lympho cytes Lepenies et al., 2007) but requires the expression of BTLA on donor cells to prevent GVHD.
Next, we asked if 6A6 could reverse established GVHD. We compared immediate with delayed administration of 6A6 ( Fig. 1 c) . Again, immediate 6A6 administration pre vented GVHD. In contrast, there was no statistical difference in weight loss or clinical scores between mice that received 6A6 14 d after aHSCT and with mice that received PIP (Fig. 1 c) .
6A6 binds to a region of BTLA that is involved in inter actions with HVEM . Thus, 6A6 might prevent GVHD by preventing HVEM and BTLA interac tions, thus blocking costimulatory signaling to donor cells (Xu et al., 2007) . Although our data indicated that host BTLA is not involved (Fig. S1 a) , we wished to test this pos sibility independently. Transfer of HVEM / donor cells caused induction of GVHD when administered with PIP ( Fig. 1 d) . The severity of GVHD caused by HVEM / donor cells was somewhat less than that caused by WT donor cells ( Fig. 1 b) , consistent with a study which found that HVEM and LIGHT are costimulatory in promoting GVHD (Xu et al., 2007) . However, 6A6 also prevented GVHD caused by HVEM / donor cells (Fig. 1 d) . These results in dicate that 6A6 prevents GVHD in a manner that is indepen dent of HVEM, suggesting it acts directly through BTLA.
Because the parentintoirradiated F1 model of aHSCT does not result in lethal GVHD, we wished to test the potency of the antiBTLA treatment in a model of complete MHC mismatch (H2 b into H2 d ) that results in lethal GVHD in un treated mice (Lu et al., 2001; Edinger et al., 2003b) . Control mice developed severe GVHD with pronounced weight loss and clinical scores of >6 ( Fig. 1 e, left and middle) and died mice as donors, using purified GFPnegative cells from Foxp3 gfp mice to remove preexisting T reg cells from the donor population. In this mixed aHSCT setting, 6A6 treatment similarly de creased the accumulation of T eff cells in both populations, but T reg cells expanded only from preexisting T reg cells (Fig. 2, f and g; and Fig. S2, e and f) . Therefore, the donor T reg/T eff cell ratio increased only among the WT donor T cells and not in the Foxp3 gfp donor T cells, as assessed by intracellular staining for endogenous Foxp3 (Fig. 2 f and Fig. S2 g ). In addition, donor derived CD4 + T cells, which were originally isolated from B6.Foxp3 gfp mice as negative for GFP expression, remained negative for Foxp3 as assessed by the Foxp3GFP reporter (Fig. S2 e, right) .
To further characterize the conditions necessary for the expansion of T reg cells, we evaluated what effects anti BTLA treatment had on T reg cells in the steady state and whether the presence of alloantigen or HVEM on host tissue is required. When unmanipulated B6.Foxp3 gfp mice received 6A6, the frequency of T eff cells, T reg cells, or the resulting ratio did not change (Fig. S3, a-d) . Similarly, although syn geneic aHSCT of CB6F1 resulted in a small decrease of T eff cells 7 d after transplant, no major accumulation of T reg cells and no increased T reg/T eff cell ratio was observed (Fig. S3 , e-h). When HVEM / donors and MHCmismatched HVEM / recipients were used, the ratio of T reg/T eff cells increased by inhibiting the accumulation of T eff cells allows the accumulation of T reg cells, resulting in an in creased T reg/T eff cell ratio (P > 0.0028; Fig. 2 d) . This re sult is in agreement with the demonstration that T reg cells maintain low levels of BTLA after activation, in contrast to conventional T cells which upregulate BTLA expression upon activation (Fig. S2 c; Hurchla et al., 2005) . Thus, 6A6 treatment increases the numbers and the frequency of donor derived T reg cells after aHSCT.
6A6 treatment could increase T reg cell frequency either by inducing Foxp3 expression in naive donor CD4 + T cells (Chen et al., 2003) or by causing in vivo expansion of preexisting donor T reg cells relative to T eff cells. To distinguish these alter natives, we used B6.Foxp3 gfp reporter mice (Fontenot et al., 2005) . We performed mixed aHSCT with WT and Foxp3 gfp 
CD4 + BTLA / population did not change in the presence of 6A6 (7.9 ± 2 vs. 7.3 ± 2%; Fig. 3, a and c) , whereas the T reg cell frequency within the CD4 + WT population increased more than threefold in the presence of 6A6 (48 ± 10 vs. 14.4 ± 5.5%; Fig. 3, a and b) .
Importantly, 6A6 treatment decreased T eff cell numbers more than fivefold from 2.6 × 10 5 ± 4.6 × 10 4 cells in the control group to 3.9 × 10 4 ± 1.4 × 10 4 (P < 0.0001; Fig. 3 d) , indicating that WTBTLA +/+ T eff cells are the main target of the antiBTLA treatment. WT and BTLA / T reg cells (Fig. S3 , i-l) as observed before (Fig. 2, d and g ). Collec tively, these results suggest that 6A6 has no effect in the steady state, does not involve HVEM, and requires allostimulation to increase the T reg/T eff cell ratio.
Because BTLA is expressed on both T eff and T reg cells, we tested whether the increased T reg/T eff cell ratio was the result of a decrease in T eff cell expansion, an increased pro liferation of T reg cells, or both by performing a mixed aHSCT using congenically marked WT BTLA +/+ and BTLA / donors. In this setting, the frequency of T reg cell within the (h-j) Recipient BALB/c mice received TCD-BM and splenocytes from T reg cell ablated or unmanipulated Foxp3 DTR mice and PIP or 6A6 as indicated. Survival curves (h), weight curves (i), and clinical scores (j) are shown for 6A6-treated mice that received a graft from either untreated (no DT) Foxp3 DTR donors (dashed line or filled squares; n = 5) or a graft from DT-treated (T reg depl.) Foxp3 DTR donors (solid line or filled circles; n = 5) and PIPtreated mice that received a graft from DT-treated or untreated (T reg depl. and no DT) Foxp3 DTR donors (dotted line or open circles; n = 10). Data are shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
T reg/BTLA / T eff cell ratio even decreased (Fig. 3 g and  Fig. S4 i) , suggesting that low expression levels of BTLA on T reg cells inhibits their expansion when proliferation of BTLA / T eff cells is not restricted.
To ask whether the inhibition of T eff cells had an effect on GVHD in the absence of T reg cells, we used C57BL/6 Foxp3 DTR mice as donors in the lethal model of GVHD. Pre treatment with diphtheria toxin reduced T reg cells by >95% in Foxp3 DTR donors. 90% of control animals died within 14 d of aHSCT, irrespective of whether or not the BM graft con tained T reg cells (Fig. 3 h) . All mice that were treated with the 6A6 antibody survived beyond day 70 (Fig. 3 h) . Mice that re ceived a graft with T reg cells and 6A6 eventually recovered to 90% of their starting weight (Fig. 3 i) and developed do not expand significantly in the presence of BTLA / T eff cells (Fig. 3 e) , confirming our observation that T reg cells expand only when T eff cells express BTLA and are inhibited by 6A6. To exclude any indirect effects on host tissues, we cotransferred purified populations of WT T reg cells together with WT or BTLA / T eff cells into BALB/c recipients, which express an allele of BTLA not recognized by 6A6 (Fig. 3 , f and g; and Fig. S4 ; Hurchla et al., 2005) . The WT T reg/ WT T eff cell ratio increased after 6A6 treatement (P < 0.0004; Fig. 3 f) as observed before (Fig. 2 g and Fig. 3 b) . In contrast, when BTLA / T eff cells were present the WT T reg/ BTLA / T eff cell ratio did not increase (Fig. 3 g) , indicat ing that the expansion of T reg cells is caused by 6A6 reduc ing the expansion of T eff cells. In this setting, the WT (blue line; n = 10) were infected with MCMV 4 wk after aHSCT and were monitored for survival. PIP-treated uninfected mice (orange line, n = 10) served as controls. Shown are cumulative data from two independent experiments. Data are shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
cells and allowing the relative expansion of naturally occur ring T reg cells. Once established, this new balance of T eff cells is sufficient to prevent GVHD permanently while allowing for intact responses to viral and bacterial pathogens, as well as GVT effects. Thus, BTLA may represent a novel therapeutic target in prevention of human GVHD. Increas ing the safety of aHSCT could potentially allow its appli cation more widely as a tolerogenic therapy in treatment of autoimmune disorders or solid organ transplantation, for which it is currently performed only experimentally (Sykes and Nikolic, 2005; Kawai et al., 2008) .
MATERIALS AND METHODS
Mice and BM transplantation. B6.SJLPtprca Pep3b/BoyJ (B6.SJL), C57BL/6, and C57BL/6 × BALB/c F1 (CB6F1) mice were obtained from The Jackson Laboratory or bred in our facility. BTLA / (Watanabe et al., 2003) , Hvem / (Wang et al., 2005) , Foxp3 gfp (Fontenot et al., 2005) , and Foxp3 DTR (Kim et al., 2007) Cell transplantation and assessment of GVHD. Mice received trans plants according to a standard protocol as previously described (Stelljes et al., 2008) . In brief, BMCs were harvested by flushing tibia and femurs of donor mice. For the nonlethal parentintoF1 model of GVHD, CB6F1 (H2 b/d ) recipients were lethally irradiated with 9 Gy total body irradiation using a 137 Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 10 7 BMCs and 10 7 splenocytes from syngeneic (H2 b/d ) or parental C57BL/6 donors (H2 b ). For the lethal model of GVHD, BALB/c (H2 d ) recipients were lethally irradiated with 8 Gy total body irradiation using a 137 Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 10 7 TCDBM alone or an additional 10 7 splenocytes from allogeneic C57BL/6 donors (H2 b ). To obtain TCDBM, cells were depleted of CD4 + and CD8 + cells by mag netic depletion (Miltenyi Biotec) according to the manufacturer's recom mendation. In experiments where a T reg cell-depleted graft from Foxp3 DTR donors was used, recipients received an intraperitoneal injection of 20 µg diphtheria toxin on the day of BMT. GVHD was monitored by calculating the loss in total body weight. Body weights were measured before transplan tation and three times a week after transplantation. Clinical GVHD intensity was scored by assessing weight loss, posture, activity, fur texture, and skin integrity (Cooke et al., 1996) . Histopathologic analyses of the bowel were performed on hematoxylin and eosin-stained tissue.
Administration of antibody.
In some experiments, mice received at the time of aHSCT, unless otherwise noted, a single intraperitoneal injection of 10-20 µg/g body weight of antiBTLA antibodies 6A6 and 6F7, whose proper ties we have previously published in detail . In brief, the IgG hamster monoclonal antibody 6A6 is specific for the C57BL/6 allele of BTLA and does not deplete BTLAexpressing cells in vivo Lepenies et al., 2007) . The IgG1 mouse monoclonal antiBTLA antibody 6F7 recognizes all known alleles of BTLA and has been shown to deplete BTLAexpressing cells in vivo. The IgG1 hamster monoclonal anti GST antibody PIP (Gronowski et al., 1999) was used as an isotype control.
Cell purification and depletion. To obtain purified populations of CD4 + Foxp3 gfp negative cells or CD4 + Foxp3 gfp positive cells in the indicated ex periments, Foxp3 gfp splenocytes were stained with CD4 + and the desired population was purified by cell sorting on the MoFlo cytometer (Dako).
lowgrade GVHD with scores ranging from 1 to 3, as seen be fore (Fig. 1 e) . Mice that received a T reg cell-depleted graft and 6A6, however, recovered only 70-80% of their starting weight and had more severe GVHD scores ranging from 3 to 5 (Fig. 3 j) . These data highlight that forced inhibition of T eff cells through BTLA (Fig. 3 d) is sufficient to prevent lethality. Nonetheless, the relative expansion of T reg cells (Fig. 3, b and f) bears biological significance, as they are required to protect the host from clinical GVHD (Fig. 3, i and j) .
Because engagement of BTLA by 6A6 inhibited T eff cell proliferation, we wondered whether this treatment allowed for antigenspecific responses to tumors and pathogens. First, we examined whether graftversustumor (GVT) activity was maintained after 6A6 treatment (Fig. 4, a-c) . We used a model of minimal residual disease after aHSCT that utilizes biolumi nescence imaging (BLI) of luciferaseexpressing A20Luc leu kemia cells (H2 d ) in vivo (Edinger et al., 2003a) . In this model, GVT activity requires cytolytic activity of T cells to control the tumor (Edinger et al., 2003b) . Transplantation of A20Luc leu kemia cells with TCDBM alone resulted in progressive tumor growth (Fig. 4, a and b) . In mice that had received a T cellcontaining graft with or without the 6A6 antibody, however, tumor was never detectable by BLI, suggesting that GVT ef fects were intact. Although all control mice died before day 45 of severe GVHD, 90% of 6A6treated mice survived beyond day 90 (Fig. 4 c) . To exclude any antibodymediated anti tumor effects, we confirmed that the 6A6 antibody does not bind to A20 cells, which was expected because of their BALB/c origin (Fig. S2 d) . To document initial tumor engraftment, we quantified the total tumor number A20GFP cells in the BM by flow cytometry 7 d after aHSCT (Fig. S3 m) .
We next examined immune responses to murine CMV (MCMV; Nguyen et al., 2008) 4 wk after aHSCT. All ani mals that had undergone syngeneic aHSCT survived for >60 d after infection (Fig. 4 d) . Of the mice in the allogeneic group that had received the PIP antibody, 70% died within 10 d of infection compared with 20% of the 6A6treated mice. Thus, although 6A6 treatment prevents GVHD, it allows for resis tance to MCMV, unlike PIPtreated control recipients.
To test the immune response against bacterial infection, animals were infected with the intracellular bacterium Listeria monocytogenes. 3 d after infection, animals that had received the PIP antibody had either higher (P = 0.0005 for liver and P = 0.1816 for spleen) or lower L. monocytogenes organ bur dens (P = 0.0227 for liver and P = 0.0059 for spleen; Fig. S3 , n-p), as has been described previously (Miura et al., 2000) . In contrast, antiBTLA-treated mice controlled infection similarly to both control groups, indicating an intact innate immune response (Fig. S3, n-p) . These preliminary results suggest that 6A6treated mice were similarly resistant to L. monocytogenes infection to unmanipulated mice.
In summary, this study demonstrates that the antiBTLA antibody 6A6 administered at the time of aHSCT prevents GVHD without the need for additional immunosuppressive therapy. The mechanism of action is through direct engage ment of BTLA on donor T cells, selectively inhibiting T eff (SigmaAldrich) and 5 µg/ml LPS and spun at 930 rcf for 1 h before being cul tured at 37°C for 24 h. 72 h after infection, cells were sorted for high GFP ex pression on a FACSAria II (BD) and stable GFP expression of >95% was confirmed several times by flow cytometry at later time points.
Models of infectious disease. For MCMV infection, mice were infected with Smith strain MCMV 4 wk after aHSCT. Virus preparation and admin istration was performed as described previously (Krug et al., 2004) . In brief, a salivary gland stock of MCMV was prepared from BALB/c mice, with a titer of 6.75 × 10 6 PFU/ml. Mice were infected intraperitoneally with a low dose of virus (10 4 PFU/mouse) and then monitored for survival. For L. monocytogenes infection, mice were infected intravenously with 2.5 × 10 4 L. monocytogenes (strain EGD; gift from E.R. Unanue, Washington Univer sity School of Medicine, St. Louis, MO) 3 mo after aHSCT. To determine organ L. monocytogenes burden at day 3 after infection, spleens and livers were homogenized in PBS plus 0.05% Triton X100. Serial dilutions of homoge nate were plated on brain heart infusion agar, and bacterial CFUs were as sessed after overnight growth at 37°C. Small portions of spleen and liver were also fixed in 10% formalin and stained with hematoxylin and eosin.
Statistical analysis. A Student's unpaired twotailed t test with a 95% con fidence interval was used for statistical analyses of body weight data, clinical scores, and cell numbers. For analyses of survival data the logrank test was used. A MannWhitney unpaired twotailed Student's t test with a 95% confidence interval was used for statistical analyses of bioluminescence data in Fig. 4 . Statistical analyses were done using Prism 4 (GraphPad Software, Inc.). FACS data are expressed as means ± SEM. All other data are presented as means ± SD. All experiments have been repeated at least once with three to five mice per group, unless stated otherwise.
Online supplemental material. Fig. S1 demonstrates that BTLA expres sion by recipient tissue does not promote GVHD and 6A6 antibody does not deplete lymphocytes. Fig. S2 shows that 6A6 treatment does not lead to donor T eff cell anergy and expands preexisting T reg cells. Fig. S3 shows that 6A6 inhibition of T eff cells and expansion of T reg cells requires allostimu lation but not HVEM expression by donor or host. Fig. S4 shows that 6A6 alters the T reg cell/effector CD4 + T cell ratio by directly inhibiting BTLA expressing T cells. Online supplemental material is available at http://www .jem.org/cgi/content/full/jem.20102017/DC1.
Purification of C57BL/6 CD4 + and BTLA / CD4 + cells was obtained from splenocytes that were depleted of CD8 + and B220 + cells by magnetic depletion (Miltenyi Biotech) according to the manufacturer's recommenda tion. Foxp3 DTR mice received intraperitoneal injections for 2 d of 20 µg diphtheria toxin per day before harvesting BM and splenocytes for aHSCT. CFSE labeling and flow cytometry. Cells were labeled with CFSE (SigmaAldrich) by being incubated for 8 min at 25°C with 1 µM CFSE at a density of 40 × 10 6 cells per ml in PBS. Labeling was quenched by incubation of cells for 1 min with an equal volume of FCS and cells were washed twice with media containing 10% (vol/vol) FCS. 50 × 10 6 total cells per mouse were injected intravenously. Single cell suspensions from spleens were ana lyzed by flow cytometry using the following antibodies for detection: K d FITC (SF11.1), CD4PECy7, APC, PerCPCy5.5, v450 (RM45) and PE (GK1.5), CD8v450 (53-6.7), anti-Armenian and Syrian hamster IgG cock tailPE, CD19APC (1D3), and annexin V-PE (BD); and CD45.1PECy7 and APC (A20), CD45.2APCeFluor780 (104), CD8APC Alexa Fluor 750 (53-6.7), CD4APC Alexa Fluor 750 (RM45), BTLAbio (6F7), and SA v450 (eBioscience). Intracellular Foxp3 was detected using the Mouse Regu latory T cell staining kit (eBioscience) with Foxp3PE or APC (FJK16s). For intracellular cytokine staining, splenocytes were first restimulated with PMA/ ionomycin for 4 h and were stained with antibodies to surface markers, fol lowed by fixation with 2% formaldehyde for 15 min at room temperature. Cells were then washed once in 0.05% saponin and stained with anticytokine antibodies (antiIL17 FITC, IL2 PE, IFN PECy7, and IL4 APC) in 0.5% saponin. All flow cytometry data were collected on a FACSCanto II (BD) and were analyzed with FlowJo software (Tree Star, Inc.).
Tumor model and assessment of GVT effects. As a tumor challenge, 2 × 10 4 A20Luc or A20GFP where administered intravenously together with the donor graft as indicated. Imaging was done as previously described (Rehemtulla et al., 2000; Edinger et al., 2003a) . In brief, dLuciferin (Bio synth AG) was reconstituted in 0.9% sodium chloride (Baxter) to a concen tration of 15 mg/ml, filtered (0.2 µm), and frozen at 80°C until use. Mice were given intraperitoneal injections at a dose of 150 mg/kg and allowed to remain active in the cage for 5 min to allow circulation of luciferin. Using the Xenogen IVIS 200 system (Caliper Life Sciences) with attached anesthesia chamber, the animals were then anesthetized with 2% isoflurane for 5 min and subsequently transferred to the imaging chamber where they continued to receive a regulated flow of isoflurane through the manifold's nose cones. The Living Image software program (Caliper Life Sciences) was used to obtain and analyze data. For all experiments, a 60s exposure time was used. To detect A20GFP in the BM, single cell suspensions from both femurs were analyzed by flow cytometry using the antibody CD19APC (1D3; BD). Cells that ex pressed high levels of CD19 and GFP were considered to be A20GFP cells.
Cell lines. The BALB/c B cell lymphoma cell line A20 was obtained from the American Type Culture Collection. To generate luciferaseexpressing A20 cells (A20Luc), a 1995bp HindIII-BamHI fragment from pGL4.23[luc2/minP] vector (Promega) containing a minimal promoter, a Luc2 coding sequence, and a SV40 late poly(A) signal was cloned into the HindIII and BamHI sites of the pcDNA3.1 + mammalian expression vector (Invitrogen) to generate pcDNA3.1 + Luc2. For stable transfections, 10 × 10 6 A20 cells/ml in complete IMDM supplemented with 10% fetal calf serum and with 30 µg/ml PvuI linearized pcDNA3.1 + Luc2 were electroporated at room temperature in 0.4ml aliquots in 0.4cm cuvettes in a Gene Pulser (BioRad Laboratories) at 240 V and 960 mF. After electroporation, cells were cultured for 24 h in IMDM supplemented with 10% fetal calf serum and then selected in the pres ence of 800 µg/ml geneticin. To generate GFPexpressing A20 cells, a retro viral reporter vector (Ranganath et al., 1998) was used that contains the coding sequence of herpes simplex virus 1 thymidine kinase, followed by an internal ribosomal entry site and GFP (HSV1TKIRESGFPRV). The retroviral vector was packaged in Phoenix A cells. Before infection, the A20 cell line was stimulated with 5 µg/ml LPS (SigmaAldrich) for 24 h. For infection, cells were cultured in retroviral supernatant supplemented with 8 µg/ml polybrene
